The Improvement of General Condition and Immunity Function of CKD After Treatment With Bailing Capsule: A Randomized Clinical Trial

IF 2.4 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

International Journal of Clinical Practice Pub Date : 2025-07-02 DOI:10.1155/ijcp/7803666

Wanjia Chen, Rong Zheng, Xiaohong Cheng, Hongtao Yang, Yueyi Deng

{"title":"The Improvement of General Condition and Immunity Function of CKD After Treatment With Bailing Capsule: A Randomized Clinical Trial","authors":"Wanjia Chen, Rong Zheng, Xiaohong Cheng, Hongtao Yang, Yueyi Deng","doi":"10.1155/ijcp/7803666","DOIUrl":null,"url":null,"abstract":"<div>\n Background: The management of chronic kidney disease (CKD) presents significant challenges, with people often exploring new treatment strategies and medications in an attempt to slow disease progression. This study seeks to evaluate the efficacy of Bailing capsules in the treatment of CKD.\n Methods: A total of 148 patients with CKD and renal and spleen qi insufficiency were included in this study. The experimental group (n = 87) received Bailing capsules in addition to the standard treatment, while the control group (n = 61) received only the standard treatment. The study used both subjective and objective endpoints, including traditional Chinese medicine (TCM) syndrome scores, routine blood tests, biochemical markers, and lymphocyte counts, to evaluate the efficacy of Bailing capsules.\n Results: After statistical analysis, we found that the experimental group showed a significant decrease in TCM syndrome scores and in various biochemical indices, including reduced levels of cystatin C, 24-h urine protein, bilirubin, gamma-glutamyl transferase, and urinary red blood cell count (p < 0.05). Additionally, the experimental group demonstrated an increase in white blood cell counts and regulation of immune function markers, such as CD3, CD4, and CD19 (p < 0.05).\n Conclusion: After treatment, the relevant indicators of CKD showed significant improvement, and the patients’ immune function was also partially regulated. Notably, no significant adverse reactions were observed that would necessitate the termination of the study. Further investigation is required to gain a deeper understanding of these findings, particularly regarding the effects of Bailing capsules on immune function regulation in CKD.\n Trial Registration: Chinese Registry of Clinical Trials: ChiCTR-IPR-17014157\n </div>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2025 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ijcp/7803666","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ijcp/7803666","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The management of chronic kidney disease (CKD) presents significant challenges, with people often exploring new treatment strategies and medications in an attempt to slow disease progression. This study seeks to evaluate the efficacy of Bailing capsules in the treatment of CKD.

Methods: A total of 148 patients with CKD and renal and spleen qi insufficiency were included in this study. The experimental group (n = 87) received Bailing capsules in addition to the standard treatment, while the control group (n = 61) received only the standard treatment. The study used both subjective and objective endpoints, including traditional Chinese medicine (TCM) syndrome scores, routine blood tests, biochemical markers, and lymphocyte counts, to evaluate the efficacy of Bailing capsules.

Results: After statistical analysis, we found that the experimental group showed a significant decrease in TCM syndrome scores and in various biochemical indices, including reduced levels of cystatin C, 24-h urine protein, bilirubin, gamma-glutamyl transferase, and urinary red blood cell count (p < 0.05). Additionally, the experimental group demonstrated an increase in white blood cell counts and regulation of immune function markers, such as CD3, CD4, and CD19 (p < 0.05).

Conclusion: After treatment, the relevant indicators of CKD showed significant improvement, and the patients’ immune function was also partially regulated. Notably, no significant adverse reactions were observed that would necessitate the termination of the study. Further investigation is required to gain a deeper understanding of these findings, particularly regarding the effects of Bailing capsules on immune function regulation in CKD.

Trial Registration: Chinese Registry of Clinical Trials: ChiCTR-IPR-17014157

Abstract Image

查看原文本刊更多论文

百灵胶囊对慢性肾病患者一般状况及免疫功能改善的随机临床研究

背景：慢性肾脏疾病（CKD）的管理面临着重大挑战，人们经常探索新的治疗策略和药物，试图减缓疾病进展。本研究旨在评价百灵胶囊治疗慢性肾病的疗效。方法：148例CKD合并肾脾气虚患者为研究对象。实验组（n = 87）在标准治疗的基础上给予百灵胶囊治疗，对照组（n = 61）只给予标准治疗。本研究采用主客观两个终点，包括中医证候评分、血常规、生化指标和淋巴细胞计数，来评价百灵胶囊的疗效。结果：经统计分析，实验组患者中医证候评分及各项生化指标均显著降低，包括胱抑素C、24小时尿蛋白、胆红素、γ -谷氨酰转移酶、尿红细胞计数(p <；0.05)。此外，实验组表现出白细胞计数增加和免疫功能标志物（如CD3、CD4和CD19）的调节(p <；0.05)。结论：治疗后CKD相关指标明显改善，患者免疫功能也得到部分调节。值得注意的是，没有观察到需要终止研究的重大不良反应。需要进一步的研究来获得对这些发现的更深入的理解，特别是关于百灵胶囊对CKD免疫功能调节的影响。试验注册：中国临床试验注册中心：ChiCTR-IPR-17014157

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Practice 医学-医学：内科

CiteScore

5.30

自引率

0.00%

发文量

274

审稿时长

3-8 weeks

期刊介绍： IJCP is a general medical journal. IJCP gives special priority to work that has international appeal. IJCP publishes: Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion] Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion] Study design and interpretation. Example. [Always peer reviewed] Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed] Meta-analyses. [Always peer reviewed] Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed] Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed] ''How to…'' papers. Example. [Always peer reviewed] Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed] Letters. [Peer reviewed at the editor''s discretion] International scope IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.